Need help finding what you are looking for?
Contact Us
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2126325
PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2126325
Oligonucleotide Synthesis Market by Offering (Synthesis Products (Consumables, Equipment), Synthesized Oligos (DNA, RNA), Oligo-based Drugs (ASO, siRNA)), Therapy Area (Rare Diseases, Neurology, Oncology), Competition - Global Forecast to 2031
PUBLISHED:
PAGES: 743 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The oligonucleotide synthesis market is projected to reach USD 32.72 billion by 2031, up from USD 14.64 billion in 2026, at a CAGR of 17.4% over the forecast period.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Offerings, Oligonucleotide-based drugs, Synthesized Oligonucleotide, Oligonucleotide Synthesis Product |
| Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Market growth is driven by several factors, including increasing demand for synthesized oligonucleotides such as primers and probes for research and diagnostic applications. Rising technological advancements in oligonucleotide synthesis are also expected to contribute to market growth during the forecast period.
By offering, the oligonucleotide-based drugs segment accounted for the largest share of the market in 2025.
The market is segmented into oligonucleotide-based drugs, synthesized oligonucleotides and oligonucleotide synthesis products (consumables and equipment). In 2025, the oligonucleotide-based drugs segment accounted for the largest share of the market. This large share reflects growing acceptance of these treatments and their proven success, especially for rare and hereditary diseases. Medications such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) target disease-causing genes, providing precise and personalized treatments. This growing demand is fueled by advancements in RNA-targeted therapies and delivery systems, the rising prevalence of genetic diseases, and significant investments in research and development of RNA-based treatments.
In 2025, North America accounted for the largest share of the overall oligonucleotide synthesis market.
The US is the largest market for oligonucleotide synthesis, driving North America's commanding share of global market revenue. This dominance is propelled by a dense ecosystem of major biopharmaceutical companies, world-class academic research institutes, and extensive venture capital investment in genomic innovation. Furthermore, a massive clinical drug pipeline featuring over 150 oligo-based therapeutics, coupled with clear, supportive regulatory frameworks from the US FDA, drives demand for complex, large-scale, high-purity GMP production at a level unmatched by any other nation.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: C-level Executives - 30%, Directors- 45%, and Others- 25%
- By Region: North America - 35%, Europe - 25%, Asia Pacific - 15%, Latin America - 10%, Middle East- 10%, and Africa - 5%
Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), LGC Limited (UK), Agilent Technologies, Inc. (US), Kaneka Corporation (Japan), Maravai LifeSciences (US), Azenta US Inc. (US), Twist Bioscience (US), and GenScript (US) are some of the key companies profiled in the report offering oligonucleotide synthesis products and synthesized oligonucleotides.
Biogen (US) Alnylam Pharmaceuticals, Inc. (US), Sarepta Therapeutics, Inc. (US), AstraZeneca (UK), Astellas Pharma Inc. (Japan), Jazz Pharmaceuticals Plc (Ireland), Nippon Shinyaku, Co. Ltd. (Japan), Ionis Pharmaceuticals, Inc. (US), and Novartis AG (Switzerland) are some of the key companies offering oligonucleotide-based drugs, profiled in the report.
Research Coverage:
This research report categorizes oligonucleotide synthesis market by offering (oligonucleotide-based drugs, synthesized oligonucleotides, oligonucleotide synthesis products); oligonucleotide-based drugs (by type: antisense oligonucleotide-based drugs, siRNA oligonucleotide-based drugs, other oligonucleotide-based drugs; by therapeutic area: rare diseases, cardiometabolic diseases, neurology, other therapeutic areas; by end user: hospitals, specialty clinics, home care settings, other end users); synthesized oligonucleotides (by oligo type: primers, probes, DNA oligos, RNA oligos, other oligos; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories); oligonucleotide synthesis products (by type: consumables, oligo synthesis equipment; by application: therapeutic applications, research applications, and diagnostic applications, by end user: biopharmaceutical & biotechnology companies, CROs & CDMOs, academic & research institutes, and diagnostic companies & laboratories), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).
The report's scope covers detailed information on the primary factors, such as drivers, restraints, challenges, and opportunities, that influence the growth of the oligonucleotide synthesis market. A thorough analysis of key industry players has been conducted to provide insights into their business overviews, product offerings, key strategies, new product launches, acquisitions, and recent developments associated with the oligonucleotide synthesis market. This report also covers the competitive analysis of upcoming startups in the oligonucleotide synthesis market ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of revenue for the oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following:
- Analysis of key drivers (Increasing use of synthesized oligos in therapeutic and diagnostic applications, technological advancements in oligonucleotide synthesis, growing government investments in life science research & synthetic biology, and growing focus on personalized medicine), restraints (Complexities associated with oligonucleotide-based drugs), opportunities (Increasing R&D investments by key players in emerging economies), and challenges (Lack of standard regulations, challenges in targeted delivery of oligonucleotides) are influencing the growth of the oligonucleotide synthesis market.
- Product Approvals: Detailed insights on newly approved products of the oligonucleotide synthesis market
- Market Development: Comprehensive information about lucrative markets - the report analyzes the oligonucleotide synthesis market across varied regions
- Market Diversification: Exhaustive information about new products, recent developments, and investments in the oligonucleotide synthesis market
- Pipeline Analysis: Comprehensive information about oligonucleotide-based drugs under clinical trials
- Competitive Assessment: In-depth assessment of market, growth strategies, and product offerings of leading players, including Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), and Merck KGaA (Germany), among others, offering oligonucleotide synthesis products and synthesized oligonucleotides. Biogen (US), Alnylam Pharmaceuticals, Inc. (US), Novartis AG (Switzerland), and Sarepta Therapeutics, Inc. (US) are key players in the oligonucleotide-based drugs segment of this market.
Product Code: BT 2680
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION & REGIONS COVERED
- 1.3.2 REGIONS COVERED
- 1.3.3 INCLUSIONS & EXCLUSIONS
- 1.3.4 YEARS CONSIDERED
- 1.3.5 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
- 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS IN OLIGONUCLEOTIDE SYNTHESIS MARKET
- 2.4 HIGH-GROWTH SEGMENTS
- 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
- 3.2 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING AND COUNTRY, 2025
- 3.3 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 3.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY OFFERING, 2026 VS. 2031 (%)
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Rising commercialization and regulatory approvals of oligonucleotide therapeutics
- 4.2.1.2 Expanding RNA therapeutics pipeline and adoption of chemically modified oligos
- 4.2.1.3 Growing use of PCR, qPCR, NGS, CRISPR, synthetic biology, and molecular diagnostics
- 4.2.1.4 Increasing outsourcing of oligonucleotide synthesis and GMP manufacturing to CROs/CDMOs
- 4.2.2 RESTRAINTS
- 4.2.2.1 Complexity of large-scale oligonucleotide manufacturing and analytical control
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Increasing government and industry investments in life sciences, RNA therapeutics, and manufacturing infrastructure
- 4.2.3.2 Expansion of oligonucleotide therapeutics into cardiometabolic and common chronic diseases
- 4.2.3.3 Growth of companion diagnostics and precision medicine
- 4.2.4 CHALLENGES
- 4.2.4.1 Lack of standard regulations
- 4.2.4.2 Delivery of oligonucleotide drugs to specific targets
- 4.2.4.3 Sustainability & waste management in phosphoramidite-based synthesis
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS & WHITE SPACES
- 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
- 4.5.1 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN THE OLIGONUCLEOTIDE-BASED DRUGS MARKET
- 4.5.2 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 OLIGONUCLEOTIDE-BASED DRUGS
- 5.1.1.1 Threat of new entrants
- 5.1.1.2 Threat of substitutes
- 5.1.1.3 Bargaining power of buyers
- 5.1.1.4 Bargaining power of suppliers
- 5.1.1.5 Intensity of competitive rivalry
- 5.1.2 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
- 5.1.2.1 Threat of new entrants
- 5.1.2.2 Threat of substitutes
- 5.1.2.3 Bargaining power of buyers
- 5.1.2.4 Bargaining power of suppliers
- 5.1.2.5 Intensity of competitive rivalry
- 5.1.1 OLIGONUCLEOTIDE-BASED DRUGS
- 5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS & FORECAST
- 5.2.3 TRENDS IN GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET
- 5.3 VALUE CHAIN ANALYSIS
- 5.4 ECOSYSTEM ANALYSIS
- 5.5 PRICING ANALYSIS
- 5.5.1 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY KEY PLAYER, 2022-2025
- 5.5.2 AVERAGE SELLING PRICE OF EQUIPMENT, BY REGION, 2025
- 5.6 KEY CONFERENCES & EVENTS, 2026-2027
- 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.8 INVESTMENT & FUNDING ACTIVITY
- 5.9 IMPACT OF 2025 US TARIFFS ON OLIGONUCLEOTIDE SYNTHESIS MARKET
- 5.9.1 INTRODUCTION
- 5.9.2 KEY TARIFF RATES
- 5.9.3 PRICE IMPACT ANALYSIS
- 5.9.4 IMPACT ON COUNTRY/REGION
- 5.9.4.1 North America
- 5.9.4.2 Europe
- 5.9.4.3 Asia Pacific
- 5.9.5 IMPACT ON END-USE INDUSTRIES
- 5.9.5.1 Hospitals
- 5.9.5.2 Specialty clinics
- 5.9.5.3 Home care settings & other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 TECHNOLOGY ANALYSIS
- 6.1.1 KEY TECHNOLOGIES
- 6.1.1.1 Solid-phase phosphoramidite synthesis and scale-up
- 6.1.1.2 Liquid-phase synthesis
- 6.1.1.3 Chemical modification & backbone engineering
- 6.1.1.4 Conjugation & targeted delivery chemistry
- 6.1.1.5 Enzymatic & novel synthesis technologies
- 6.1.1.6 High-throughput automated oligonucleotide synthesis
- 6.1.1.7 Purification & analytical characterization
- 6.1.2 ADJACENT TECHNOLOGIES
- 6.1.2.1 Molecular biology & genomic technologies
- 6.1.2.2 Synthetic biology & gene synthesis
- 6.1.3 COMPLEMENTARY TECHNOLOGIES
- 6.1.3.1 Advanced oligonucleotide delivery technologies
- 6.1.3.2 AI-assisted oligonucleotide design
- 6.1.1 KEY TECHNOLOGIES
- 6.2 TECHNOLOGY/PRODUCT ROADMAP
- 6.3 FUTURE APPLICATIONS
- 6.4 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
- 6.4.1 TOP USE CASES & MARKET POTENTIAL
- 6.4.2 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
- 6.4.3 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET
- 6.5 PATENT ANALYSIS & INNOVATIONS
- 6.5.1 OLIGONUCLEOTIDE SYNTHESIS MARKET: PATENT ANALYSIS, 2015-2025
- 6.5.2 KEY INNOVATIONS
7 SUSTAINABILITY & REGULATORY LANDSCAPE
- 7.1 REGIONAL REGULATIONS & COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 REGULATORY FRAMEWORK & REIMBURSEMENT
- 7.1.2.1 North America
- 7.1.2.2 Europe
- 7.1.2.3 Asia Pacific
- 7.1.2.4 Rest of the World
- 7.1.3 INDUSTRY STANDARDS
- 7.2 REIMBURSEMENT SCENARIO
- 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES
- 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 KEY BUYING CRITERIA, BY END USER
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS FROM END USERS
- 8.5 MARKET PROFITABILITY
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING
- 9.1 INTRODUCTION
- 9.2 OLIGONUCLEOTIDE-BASED DRUGS
- 9.2.1 RECURRING CONSUMABLES DEMAND, AUTOMATION UPGRADES, AND ADVANCED SCREENING PLATFORMS TO DRIVE GROWTH
- 9.3 SYNTHESIZED OLIGONUCLEOTIDES
- 9.3.1 GROWING ADOPTION OF PCR, QPCR, NGS, AND CRISPR-BASED GENOME EDITING TO GENERATE SUBSTANTIAL DEMAND FOR CUSTOM PRIMERS
- 9.4 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS
- 9.4.1 INCREASING INSTALLATION OF AUTOMATED OLIGONUCLEOTIDE SYNTHESIZERS TO SUPPORT MARKET GROWTH
10 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE
- 10.1 INTRODUCTION
- 10.2 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS
- 10.2.1 ASO-BASED DRUGS ACCOUNTED FOR LARGEST MARKET SHARE DUE TO THEIR ESTABLISHED CLINICAL SUCCESS ACROSS RARE AND NEUROLOGICAL DISEASES
- 10.3 SIRNA OLIGONUCLEOTIDE-BASED DRUGS
- 10.3.1 EXPANDING COMMERCIAL ADOPTION AND STRONG LATE-STAGE PIPELINES TO DRIVE GROWTH
- 10.4 OTHER OLIGONUCLEOTIDE-BASED DRUGS
11 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA
- 11.1 INTRODUCTION
- 11.2 RARE DISEASES
- 11.2.1 GROWING APPROVALS FOR ORPHAN DISEASES TO MAKE RARE DISEASES LARGEST THERAPEUTIC AREA FOR OLIGONUCLEOTIDE THERAPEUTICS
- 11.3 NEUROLOGICAL DISORDERS
- 11.3.1 COMMERCIAL SUCCESS OF RNA-TARGETED THERAPIES TO CONTINUE TO STRENGTHEN NEUROLOGY SEGMENT
- 11.4 CARDIOMETABOLIC DISEASES
- 11.4.1 EXPANDING RNA THERAPEUTICS FOR CARDIOVASCULAR DISEASES TO MAKE CARDIOMETABOLIC DISEASES FASTEST-GROWING THERAPEUTIC AREA
- 11.5 OTHER THERAPEUTIC AREAS
12 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER
- 12.1 INTRODUCTION
- 12.2 SPECIALTY CLINICS
- 12.2.1 GROWING NETWORK OF SPECIALIZED RARE DISEASE TREATMENT CENTERS TO MAINTAIN SPECIALTY CLINICS AS LARGEST END-USER SEGMENT
- 12.3 HOSPITALS
- 12.3.1 COMPLEX PATIENT MANAGEMENT AND ADMINISTRATION OF ADVANCED OLIGONUCLEOTIDE THERAPIES TO CONTINUE TO SUPPORT HOSPITAL DEMAND
- 12.4 HOME CARE SETTINGS
- 12.4.1 SHIFT TOWARD CONVENIENT DOSING AND SELF-ADMINISTRATION TO MAKE HOME CARE SETTINGS FASTEST-GROWING END-USER SEGMENT
- 12.5 OTHER END USERS
13 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE
- 13.1 INTRODUCTION
- 13.2 PRIMERS
- 13.2.1 WIDESPREAD USE OF PRIMERS ACROSS RESEARCH, DIAGNOSTICS, AND THERAPEUTIC DEVELOPMENT TO FUEL GROWTH
- 13.3 PROBES
- 13.3.1 EXPANDING MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE STRONG DEMAND FOR PROBES
- 13.4 DNA OLIGONUCLEOTIDES
- 13.4.1 BROAD APPLICABILITY ACROSS LIFE SCIENCE RESEARCH AND DIAGNOSTICS TO DRIVE SIGNIFICANT MARKET SHARE FOR DNA OLIGOS
- 13.5 RNA OLIGONUCLEOTIDES
- 13.5.1 RAPID GROWTH OF RNA THERAPEUTICS AND GENE-EDITING TECHNOLOGIES TO DRIVE MARKET MOMENTUM FOR RNA OLIGOS
- 13.6 OTHER OLIGONUCLEOTIDES
14 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE
- 14.1 INTRODUCTION
- 14.2 CUSTOM OLIGONUCLEOTIDES
- 14.2.1 RAPID CLINICAL AND COMMERCIAL EXPANSION OF CHEMICALLY MODIFIED ANTISENSE AND SIRNA THERAPEUTICS TO MAKE CUSTOM OLIGONUCLEOTIDES FASTEST-GROWING SEGMENT
- 14.3 PREDESIGNED OLIGONUCLEOTIDES
- 14.3.1 PREDESIGNED OLIGONUCLEOTIDES CONTINUE TO WITNESS STEADY DEMAND OWING TO WIDESPREAD USE IN ROUTINE RESEARCH AND MOLECULAR DIAGNOSTICS
15 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION
- 15.1 INTRODUCTION
- 15.2 RESEARCH APPLICATIONS
- 15.2.1 PCR
- 15.2.1.1 Widespread adoption of PCR across life science research to drive market growth
- 15.2.2 NGS
- 15.2.2.1 Sequencing to continue to expand with increasing adoption of next-generation sequencing technologies
- 15.2.3 OTHER RESEARCH APPLICATIONS
- 15.2.1 PCR
- 15.3 THERAEPUTIC DEVELOPMENT
- 15.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO SUPPORT GROWTH OF MARKET FOR THERAPEUTIC DEVELOPMENT APPLICATIONS
- 15.4 DIAGNOSTIC APPLICATIONS
- 15.4.1 INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO EXPAND MARKET FOR DIAGNOSTIC APPLICATIONS
16 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER
- 16.1 INTRODUCTION
- 16.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 16.2.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO MAKE PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES LARGEST END-USER SEGMENT
- 16.3 CROS & CDMOS
- 16.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE DRUG DEVELOPMENT TO DRIVE FASTEST GROWTH AMONG CROS & CDMOS
- 16.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES
- 16.4.1 GROWING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE TO DRIVE DEMAND
- 16.5 ACADEMIC & RESEARCH INSTITUTES
- 16.5.1 EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH TO SUSTAIN DEMAND FROM ACADEMIC & RESEARCH INSTITUTES
17 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE
- 17.1 INTRODUCTION
- 17.2 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES
- 17.2.1 OLIGONUCLEOTIDE SYNTHESIS REAGENTS
- 17.2.1.1 Phosphoramidite building blocks
- 17.2.1.1.1 DNA phosphoramidites
- 17.2.1.1.1.1 Steady, high-volume primer, probe, and gene-synthesis demand to anchor DNA phosphoramidites as largest phosphoramidite revenue category
- 17.2.1.1.2 RNA phosphoramidites
- 17.2.1.1.2.1 Expansion of siRNA and CRISPR guide RNA therapeutic pipeline to make RNA phosphoramidites fastest-growing phosphoramidite category
- 17.2.1.1.3 Modified phosphoramidites
- 17.2.1.1.3.1 Modified phosphoramidites to continue to gain importance as oligonucleotide complexity increases
- 17.2.1.1.1 DNA phosphoramidites
- 17.2.1.2 Activators/Coupling reagents
- 17.2.1.2.1 Migration from standard tetrazole to ETT- and BTT-based activators to raise coupling efficiency in GMP-scale RNA and modified-oligo synthesis
- 17.2.1.3 Deprotection reagents
- 17.2.1.3.1 Rising synthesis throughput and demand for milder, modification-compatible deprotection chemistries to sustain detritylation reagent consumption
- 17.2.1.4 Capping reagents
- 17.2.1.4.1 Tightening n-1 impurity specifications for therapeutic oligonucleotides to lift demand for validated, high-purity capping reagent lots
- 17.2.1.5 Other reagents
- 17.2.1.1 Phosphoramidite building blocks
- 17.2.2 SOLID SUPPORTS
- 17.2.2.1 Shift toward high-loading co-polymer CPG and single-use synthesis cassettes to support long-chain, GMP-scale oligonucleotide production
- 17.2.3 OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES
- 17.2.3.1 Tightening GMP purity specifications for therapeutic oligonucleotides to drive demand for purification and QC consumables
- 17.2.1 OLIGONUCLEOTIDE SYNTHESIS REAGENTS
- 17.3 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT
- 17.3.1 ADOPTION OF FLOW-THROUGH, GMP-COMPLIANT SYNTHESIS PLATFORMS TO SCALE OLIGONUCLEOTIDE MANUFACTURING FROM RESEARCH THROUGH COMMERCIAL PRODUCTION
18 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION
- 18.1 INTRODUCTION
- 18.2 RESEARCH APPLICATIONS
- 18.2.1 HIGH-VOLUME CONSUMPTION OF SYNTHESIS PRODUCTS ACROSS GENOMICS AND MOLECULAR BIOLOGY RESEARCH TO DRIVE GROWTH
- 18.3 THERAPEUTIC DEVELOPMENT
- 18.3.1 EXPANDING OLIGONUCLEOTIDE DRUG PIPELINES TO BOOST MARKET
- 18.4 DIAGNOSTIC APPLICATIONS
- 18.4.1 DIAGNOSTICS APPLICATIONS TO CONTINUE TO EXPAND WITH INCREASING ADOPTION OF MOLECULAR DIAGNOSTICS AND PRECISION MEDICINE
19 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER
- 19.1 INTRODUCTION
- 19.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
- 19.2.1 INCREASING INVESTMENTS IN OLIGONUCLEOTIDE DRUG DEVELOPMENT AND MANUFACTURING TO SUPPORT MARKET GROWTH
- 19.3 CROS & CDMOS
- 19.3.1 INCREASING OUTSOURCING OF OLIGONUCLEOTIDE MANUFACTURING TO DRIVE MARKET GROWTH
- 19.4 DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES
- 19.4.1 EXPANDED USE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS WITH GROWTH OF MOLECULAR DIAGNOSTICS TO BOOST DEMAND
- 19.5 ACADEMIC & RESEARCH INSTITUTES
- 19.5.1 ACADEMICS & RESEARCH INSTITUTES TO CONTINUE TO PROVIDE STABLE DEMAND DRIVEN BY EXPANDING GENOMICS AND LIFE SCIENCE RESEARCH
20 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION
- 20.1 INTRODUCTION
- 20.2 NORTH AMERICA
- 20.2.1 US
- 20.2.1.1 Mature ecosystem across oligo-based therapeutics, synthesized oligonucleotides, and oligonucleotide synthesis products to drive market growth
- 20.2.2 CANADA
- 20.2.2.1 Strong academic research ecosystem to support market growth
- 20.2.1 US
- 20.3 EUROPE
- 20.3.1 GERMANY
- 20.3.1.1 Established capabilities for development and manufacturing of oligo-based therapeutics to drive market growth
- 20.3.2 UK
- 20.3.2.1 Established national programs to encourage utilization of oligonucleotide synthesis products
- 20.3.3 FRANCE
- 20.3.3.1 Increase in RNA-related research by biotechnology companies and academic institutions to drive market growth
- 20.3.4 ITALY
- 20.3.4.1 High demand for molecular diagnostics to favor adoption of oligonucleotide synthesis products
- 20.3.5 SPAIN
- 20.3.5.1 Government organizations investing in oligonucleotide-related research activities to drive market growth
- 20.3.6 REST OF EUROPE
- 20.3.1 GERMANY
- 20.4 ASIA PACIFIC
- 20.4.1 JAPAN
- 20.4.1.1 Expanding collaboration between pharma companies and academic institutions for development of oligonucleotide therapeutics to drive market growth
- 20.4.2 CHINA
- 20.4.2.1 Robust network of domestic companies offering oligonucleotide products to support market growth
- 20.4.3 INDIA
- 20.4.3.1 Expanding presence of domestic service providers to offer high-quality DNA and RNA oligonucleotides for research and diagnostics
- 20.4.4 SOUTH KOREA
- 20.4.4.1 High demand for custom oligonucleotide synthesis services to support market growth
- 20.4.5 AUSTRALIA
- 20.4.5.1 Well-established biomedical research sector to favor utilization of oligonucleotide synthesis products
- 20.4.6 REST OF ASIA PACIFIC
- 20.4.1 JAPAN
- 20.5 LATIN AMERICA
- 20.5.1 BRAZIL
- 20.5.1.1 Government initiatives aimed at strengthening genomic surveillance to offer market expansion opportunities
- 20.5.2 MEXICO
- 20.5.2.1 Growing network of pharmaceutical manufacturers and diagnostic laboratories to offer market expansion opportunities
- 20.5.3 ARGENTINA
- 20.5.3.1 Increasing investment by academic institutions in oligonucleotide-based research to offer market expansion opportunities
- 20.5.4 REST OF LATIN AMERICA
- 20.5.1 BRAZIL
- 20.6 MIDDLE EAST
- 20.6.1 GCC COUNTRIES
- 20.6.1.1 Saudi Arabia
- 20.6.1.1.1 National genomics initiatives to encourage adoption of oligonucleotide synthesis products
- 20.6.1.2 UAE
- 20.6.1.2.1 Government-driven initiatives and substantial investments to improve UAE's capabilities in life science industry
- 20.6.1.3 Rest of GCC Countries
- 20.6.1.1 Saudi Arabia
- 20.6.2 REST OF MIDDLE EAST
- 20.6.1 GCC COUNTRIES
- 20.7 AFRICA
- 20.7.1 GROWING INVESTMENTS IN PUBLIC HEALTH DIAGNOSTICS AND GENOMIC SURVEILLANCE ACTIVITIES TO DRIVE MARKET GROWTH
21 COMPETITIVE LANDSCAPE
- 21.1 INTRODUCTION
- 21.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 21.2.1 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023-2026
- 21.2.2 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023-2026
- 21.3 REVENUE ANALYSIS, 2021-2025
- 21.3.1 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2021-2025
- 21.3.2 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021-2025
- 21.4 MARKET SHARE ANALYSIS, 2025
- 21.4.1 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025
- 21.4.2 MARKET SHARE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025
- 21.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE-BASED DRUGS MARKET), 2025
- 21.5.1 STARS
- 21.5.2 EMERGING LEADERS
- 21.5.3 PERVASIVE PLAYERS
- 21.5.4 PARTICIPANTS
- 21.5.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2025
- 21.5.5.1 Company footprint
- 21.5.5.2 Region footprint
- 21.5.5.3 Drug type footprint
- 21.5.5.4 Therapeutic area footprint
- 21.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET), 2025
- 21.6.1 STARS
- 21.6.2 EMERGING LEADERS
- 21.6.3 PERVASIVE PLAYERS
- 21.6.4 PARTICIPANTS
- 21.6.5 COMPANY FOOTPRINT: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2025
- 21.6.5.1 Company footprint
- 21.6.5.2 Region footprint
- 21.6.5.3 Product type footprint
- 21.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 21.7.1 PROGRESSIVE COMPANIES
- 21.7.2 RESPONSIVE COMPANIES
- 21.7.3 DYNAMIC COMPANIES
- 21.7.4 STARTING BLOCKS
- 21.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 21.7.5.1 Detailed list of key startups/SMEs
- 21.7.5.2 Competitive benchmarking of key startups/SMEs
- 21.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
- 21.9 COMPANY VALUATION & FINANCIAL METRICS
- 21.9.1 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES PLAYERS
- 21.9.2 COMPANY VALUATION & FINANCIAL METRICS FOR OLIGONUCLEOTIDE-BASE DRUGS PLAYERS
- 21.10 COMPETITIVE SCENARIO
- 21.10.1 PRODUCT APPROVALS
- 21.10.2 DEALS
- 21.10.3 EXPANSIONS
22 COMPANY PROFILES
- 22.1 OLIGONUCLEOTIDE-BASED DRUG COMPANIES
- 22.1.1 ALNYLAM PHARMACEUTICALS, INC.
- 22.1.1.1 Business overview
- 22.1.1.2 Products offered
- 22.1.1.3 Recent developments
- 22.1.1.3.1 Product approvals
- 22.1.1.3.2 Deals
- 22.1.1.3.3 Expansions
- 22.1.1.4 MnM view
- 22.1.1.4.1 Key strengths
- 22.1.1.4.2 Strategic choices
- 22.1.1.4.3 Weaknesses & competitive threats
- 22.1.2 BIOGEN INC.
- 22.1.2.1 Business overview
- 22.1.2.2 Products offered
- 22.1.2.3 Recent developments
- 22.1.2.3.1 Product approvals
- 22.1.2.3.2 Deals
- 22.1.2.3.3 Expansions
- 22.1.2.4 MnM view
- 22.1.2.4.1 Key strengths
- 22.1.2.4.2 Strategic choices
- 22.1.2.4.3 Weaknesses & competitive threats
- 22.1.3 NOVARTIS AG
- 22.1.3.1 Business overview
- 22.1.3.2 Products offered
- 22.1.3.3 Recent developments
- 22.1.3.3.1 Product approvals
- 22.1.3.3.2 Deals
- 22.1.3.4 MnM view
- 22.1.3.4.1 Key strengths
- 22.1.3.4.2 Strategic choices
- 22.1.3.4.3 Weaknesses & competitive threats
- 22.1.4 SAREPTA THERAPEUTICS, INC.
- 22.1.4.1 Business overview
- 22.1.4.2 Products offered
- 22.1.4.3 Recent developments
- 22.1.4.3.1 Product approvals
- 22.1.4.3.2 Deals
- 22.1.4.3.3 Expansions
- 22.1.4.4 MnM view
- 22.1.4.4.1 Key strengths
- 22.1.4.4.2 Strategic choices
- 22.1.4.4.3 Weaknesses & competitive threats
- 22.1.5 ASTELLAS PHARMA INC.
- 22.1.5.1 Business overview
- 22.1.5.2 Products offered
- 22.1.5.3 Recent developments
- 22.1.5.3.1 Product approvals
- 22.1.5.3.2 Deals
- 22.1.5.4 MnM view
- 22.1.5.4.1 Key strengths
- 22.1.5.4.2 Strategic choices
- 22.1.5.4.3 Weaknesses & competitive threats
- 22.1.6 ASTRAZENECA
- 22.1.6.1 Business overview
- 22.1.6.2 Products offered
- 22.1.6.3 Recent developments
- 22.1.6.3.1 Product approvals
- 22.1.6.3.2 Deals
- 22.1.7 JAZZ PHARMACEUTICALS PLC
- 22.1.7.1 Business overview
- 22.1.7.2 Products offered
- 22.1.8 GERON CORPORATION
- 22.1.8.1 Business overview
- 22.1.8.2 Products offered
- 22.1.8.3 Recent developments
- 22.1.8.3.1 Product approvals
- 22.1.8.3.2 Deals
- 22.1.9 IONIS PHARMACEUTICALS, INC.
- 22.1.9.1 Business overview
- 22.1.9.2 Products offered
- 22.1.9.3 Recent developments
- 22.1.9.3.1 Product approvals
- 22.1.9.3.2 Deals
- 22.1.9.3.3 Expansions
- 22.1.10 NIPPON SHINYAKU, CO. LTD. (NS PHARMA, INC.)
- 22.1.10.1 Business overview
- 22.1.10.2 Products offered
- 22.1.10.3 Recent developments
- 22.1.10.3.1 Deals
- 22.1.11 NOVO NORDISK A/S
- 22.1.11.1 Business overview
- 22.1.11.2 Products offered
- 22.1.11.3 Recent developments
- 22.1.11.3.1 Product approvals
- 22.1.12 ARROWHEAD PHARMACEUTICALS, INC.
- 22.1.12.1 Business overview
- 22.1.12.2 Products offered
- 22.1.12.3 Recent developments
- 22.1.12.3.1 Product launches & approvals
- 22.1.12.3.2 Deals
- 22.1.13 SANOFI
- 22.1.13.1 Business overview
- 22.1.13.2 Products offered
- 22.1.13.3 Recent developments
- 22.1.13.3.1 Product approvals
- 22.1.1 ALNYLAM PHARMACEUTICALS, INC.
- 22.2 OLIGONUCLEOTIDE SYNTHESIS & SYNTHESIZED OLIGONUCLEOTIDE COMPANIES
- 22.2.1 THERMO FISHER SCIENTIFIC INC.
- 22.2.1.1 Business overview
- 22.2.1.2 Products offered
- 22.2.1.3 Recent developments
- 22.2.1.3.1 Expansions
- 22.2.1.4 MnM view
- 22.2.1.4.1 Key strengths
- 22.2.1.4.2 Strategic choices
- 22.2.1.4.3 Weaknesses & competitive threats
- 22.2.2 MERCK KGAA
- 22.2.2.1 Business overview
- 22.2.2.2 Products offered
- 22.2.2.3 Recent developments
- 22.2.2.3.1 Expansions
- 22.2.2.4 MnM view
- 22.2.2.4.1 Key strengths
- 22.2.2.4.2 Strategic choices
- 22.2.2.4.3 Weaknesses & competitive threats
- 22.2.3 DANAHER CORPORATION
- 22.2.3.1 Business overview
- 22.2.3.2 Products offered
- 22.2.3.3 Recent developments
- 22.2.3.3.1 Service launches
- 22.2.3.3.2 Deals
- 22.2.3.3.3 Expansions
- 22.2.3.4 MnM view
- 22.2.3.4.1 Key strengths
- 22.2.3.4.2 Strategic choices
- 22.2.3.4.3 Weaknesses & competitive threats
- 22.2.4 EUROFINS SCIENTIFIC
- 22.2.4.1 Business overview
- 22.2.4.2 Products offered
- 22.2.4.3 Recent developments
- 22.2.4.3.1 Deals
- 22.2.4.3.2 Expansions
- 22.2.4.4 MnM view
- 22.2.4.4.1 Key strengths
- 22.2.4.4.2 Strategic choices
- 22.2.4.4.3 Weaknesses & competitive threats
- 22.2.5 AGILENT TECHNOLOGIES, INC.
- 22.2.5.1 Business overview
- 22.2.5.2 Products offered
- 22.2.5.3 Recent developments
- 22.2.5.3.1 Deals
- 22.2.5.3.2 Expansions
- 22.2.6 LGC LIMITED
- 22.2.6.1 Business overview
- 22.2.6.2 Products offered
- 22.2.6.3 Recent developments
- 22.2.6.3.1 Deals
- 22.2.6.4 MnM view
- 22.2.6.4.1 Key strengths
- 22.2.6.4.2 Strategic choices
- 22.2.6.4.3 Weaknesses & competitive threats
- 22.2.7 TWIST BIOSCIENCE
- 22.2.7.1 Business overview
- 22.2.7.2 Products offered
- 22.2.7.3 Recent developments
- 22.2.7.3.1 Product/Service launches
- 22.2.7.3.2 Deals
- 22.2.8 GENSCRIPT
- 22.2.8.1 Business overview
- 22.2.8.2 Products offered
- 22.2.8.3 Recent developments
- 22.2.8.3.1 Product/Service launches
- 22.2.8.3.2 Deals
- 22.2.8.3.3 Expansions
- 22.2.9 MARAVAI LIFESCIENCES
- 22.2.9.1 Business overview
- 22.2.9.2 Products offered
- 22.2.9.3 Recent developments
- 22.2.9.3.1 Product/Service launches
- 22.2.9.3.2 Deals
- 22.2.9.3.3 Expansions
- 22.2.9.4 MnM view
- 22.2.9.4.1 Key strengths
- 22.2.9.4.2 Strategic choices
- 22.2.9.4.3 Weaknesses & competitive threats
- 22.2.10 KANEKA CORPORATION
- 22.2.10.1 Business overview
- 22.2.10.2 Products offered
- 22.2.10.3 Recent developments
- 22.2.10.3.1 Expansions
- 22.2.11 AZENTA US INC.
- 22.2.11.1 Business overview
- 22.2.11.2 Products offered
- 22.2.11.3 Recent developments
- 22.2.11.3.1 Product/Service launches
- 22.2.11.3.2 Deals
- 22.2.12 OLIGOMAKER APS (PART OF TAG COPENHAGEN A/S)
- 22.2.12.1 Business overview
- 22.2.12.2 Products offered
- 22.2.13 BIOLEGIO B.V.
- 22.2.13.1 Business overview
- 22.2.13.2 Products offered
- 22.2.14 BIOLYTIC LAB PERFORMANCE, INC.
- 22.2.14.1 Business overview
- 22.2.14.2 Products offered
- 22.2.14.3 Recent developments
- 22.2.14.3.1 Product/Service launches
- 22.2.15 REVVITY (THROUGH SUBSIDIARY HORIZON DISCOVERY LTD.)
- 22.2.15.1 Business overview
- 22.2.15.2 Products offered
- 22.2.15.3 Recent developments
- 22.2.15.3.1 Product/Service launches
- 22.2.16 BIO-SYNTHESIS, INC.
- 22.2.16.1 Business overview
- 22.2.16.2 Products offered
- 22.2.17 CREATIVE BIOGENE
- 22.2.17.1 Business overview
- 22.2.17.2 Products offered
- 22.2.18 REPROCELL INC. (THROUGH SUBSIDIARY BIOSERVE)
- 22.2.18.1 Business overview
- 22.2.18.2 Products offered
- 22.2.19 BIOCOMMA LIMITED
- 22.2.19.1 Business overview
- 22.2.19.2 Products offered
- 22.2.1 THERMO FISHER SCIENTIFIC INC.
23 RESEARCH METHODOLOGY
- 23.1 RESEARCH DATA
- 23.1.1 SECONDARY DATA
- 23.1.1.1 Key secondary sources
- 23.1.1.2 Key data from secondary research
- 23.1.2 PRIMARY DATA
- 23.1.2.1 Key primary participants
- 23.1.2.2 Breakdown of primary interviews
- 23.1.2.3 Key data from primary sources
- 23.1.1 SECONDARY DATA
- 23.2 MARKET SIZE ESTIMATION
- 23.2.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025
- 23.2.1.1 Approach 1: Company revenue analysis-based estimation (bottom-up)
- 23.2.1.2 Approach 2: Secondary research
- 23.2.1.3 Approach 3: Primary research
- 23.2.1.4 Key industry insights
- 23.2.1.5 Approach 3: MnM repository analysis
- 23.2.2 SEGMENTAL MARKET SIZE ESTIMATION, 2025
- 23.2.1 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025
- 23.3 MARKET GROWTH RATE PROJECTIONS
- 23.4 DATA TRIANGULATION
- 23.5 RESEARCH ASSUMPTIONS
- 23.6 RESEARCH LIMITATIONS & RISK ASSESSMENT
24 APPENDIX
- 24.1 DISCUSSION GUIDE
- 24.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 24.3 CUSTOMIZATION OPTIONS
- 24.4 RELATED REPORTS
- 24.5 AUTHOR DETAILS
Product Code: BT 2680
List of Tables
- TABLE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET: INCLUSIONS & EXCLUSIONS
- TABLE 2 OLIGONUCLEOTIDE SYNTHESIS MARKET: IMPACT ANALYSIS
- TABLE 3 OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
- TABLE 4 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER'S FIVE FORCES ANALYSIS
- TABLE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET: ROLE IN ECOSYSTEM
- TABLE 6 AVERAGE SELLING PRICE TREND OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS, BY KEY PLAYER, 2023-2025
- TABLE 7 AVERAGE SELLING PRICE TREND FOR OLIGONUCLEOTIDE-BASED DRUGS, BY KEY PLAYER, 2023-2025
- TABLE 8 AVERAGE SELLING PRICE OF OLIGONUCLEOTIDE SYNTHESIZERS, BY REGION, 2025
- TABLE 9 OLIGONUCLEOTIDE SYNTHESIS MARKET: KEY CONFERENCES & EVENTS, 2026-2027
- TABLE 10 US-ADJUSTED RECIPROCAL TARIFF RATES
- TABLE 11 CASE STUDIES OF AI IMPLEMENTATION IN OLIGONUCLEOTIDE SYNTHESIS MARKETCASE STUDIES OF AI IMPLEMENTATION IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET
- TABLE 12 CLIENT'S READINESS TO ADOPT GENERATIVE AI IN OLIGONUCLEOTIDE SYNTHESIS MARKET
- TABLE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET: INDICATIVE LIST OF PATENTS, 2025
- TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 17 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 18 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- TABLE 19 REIMBURSEMENT SCENARIO FOR MAJOR COMMERCIAL OLIGONUCLEOTIDE THERAPEUTICS
- TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE (%)
- TABLE 21 KEY BUYING CRITERIA, BY END USER
- TABLE 22 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 23 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 24 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 25 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 26 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 27 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 28 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 29 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 30 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY PRODUCT, 2024-2031 (VIALS/PREFILLED SYRINGES)
- TABLE 31 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 32 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 33 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 34 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 35 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 36 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 37 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 38 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 39 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 40 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 41 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 42 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 43 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 44 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 45 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 46 APPROVED ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS
- TABLE 47 ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 48 NORTH AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 49 EUROPE: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 50 ASIA PACIFIC: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 51 LATIN AMERICA: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 52 MIDDLE EAST: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 53 GCC COUNTRIES: ANTISENSE OLIGONUCLEOTIDE (ASO)-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 54 APPROVED SIRNA OLIGONUCLEOTIDE-BASED DRUGS
- TABLE 55 SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 56 NORTH AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 57 EUROPE: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 58 ASIA PACIFIC: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 59 LATIN AMERICA: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 60 MIDDLE EAST: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 61 GCC COUNTRIES: SIRNA OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 62 OTHER APPROVED OLIGONUCLEOTIDE-BASED DRUGS
- TABLE 63 OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 64 NORTH AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 65 EUROPE: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 66 ASIA PACIFIC: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 67 LATIN AMERICA: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 68 MIDDLE EAST: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 69 GCC COUNTRIES: OTHER OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 70 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 71 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 72 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 73 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 74 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 75 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 76 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 77 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR RARE DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 78 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 80 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 83 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 84 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR NEUROLOGICAL DISORDERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 85 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 86 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 87 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 88 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 89 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 90 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 91 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR CARDIOMETABOLIC DISEASES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 92 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 93 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 94 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 95 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 96 OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 97 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 98 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 99 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 100 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 101 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 102 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 103 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR SPECIALTY CLINICS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 104 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 105 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 106 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 107 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 108 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 109 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 110 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 111 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 112 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 113 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 114 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 115 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 116 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 117 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 118 OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 119 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 120 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 121 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 122 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 123 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 124 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET FOR OTHER END USERS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 125 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 126 PRIMERS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 127 NORTH AMERICA: PRIMERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 128 EUROPE: PRIMERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 129 ASIA PACIFIC: PRIMERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 130 LATIN AMERICA: PRIMERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 131 MIDDLE EAST: PRIMERS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 132 GCC COUNTRIES: PRIMERS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 133 PROBES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 134 NORTH AMERICA: PROBES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 135 EUROPE: PROBES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 136 ASIA PACIFIC: PROBES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 137 LATIN AMERICA: PROBES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 138 MIDDLE EAST: PROBES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 139 GCC COUNTRIES: PROBES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 140 DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 141 NORTH AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 142 EUROPE: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 143 ASIA PACIFIC: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 144 LATIN AMERICA: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 145 MIDDLE EAST: DNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 146 GCC COUNTRIES: DNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 147 RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 148 NORTH AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 149 EUROPE: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 150 ASIA PACIFIC: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 151 LATIN AMERICA: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 152 MIDDLE EAST: RNA OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 153 GCC COUNTRIES: RNA OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 154 OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 155 NORTH AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 156 EUROPE: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 157 ASIA PACIFIC: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 158 LATIN AMERICA: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 159 MIDDLE EAST: OTHER OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 160 GCC COUNTRIES: OTHER OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 161 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 162 CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 163 NORTH AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 164 EUROPE: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 165 ASIA PACIFIC: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 166 LATIN AMERICA: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 167 MIDDLE EAST: CUSTOM OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 168 GCC COUNTRIES: CUSTOM OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 169 PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 170 NORTH AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 171 EUROPE: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 172 ASIA PACIFIC: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 173 LATIN AMERICA: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 174 MIDDLE EAST: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 175 GCC COUNTRIES: PREDESIGNED OLIGONUCLEOTIDES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 176 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 177 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 178 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 179 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 180 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 181 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 182 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 183 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 184 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 185 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 186 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 187 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 188 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 189 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 190 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 191 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PCR APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 192 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 193 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 194 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 195 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 196 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 197 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 198 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR NGS APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 199 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 200 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 201 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 202 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 203 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 204 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 205 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR OTHER RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 206 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
- TABLE 207 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAEPUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 208 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 209 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 210 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 211 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
- TABLE 212 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 213 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 214 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 215 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 216 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 217 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 218 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 219 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 220 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 221 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 222 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 223 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 224 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 225 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 226 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 227 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 228 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 229 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 230 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 231 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 232 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 233 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 234 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 235 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 236 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 237 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 238 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 239 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 240 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 241 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 242 SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 243 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 244 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 245 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 246 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 247 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 248 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 249 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 250 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 251 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 252 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 253 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 254 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 255 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 256 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 257 OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 258 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 259 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 260 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 261 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 262 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 263 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 264 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 265 OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 266 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 267 NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 268 EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 269 ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 270 LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 271 MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 272 GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 273 PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 274 DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 275 NORTH AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 276 EUROPE: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 277 ASIA PACIFIC: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 278 LATIN AMERICA: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 279 MIDDLE EAST: DNA PHOSPHORAMIDITES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 280 GCC COUNTRIES: DNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 281 RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 282 NORTH AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 283 EUROPE: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 284 ASIA PACIFIC: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 285 LATIN AMERICA: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 286 MIDDLE EAST: RNA PHOSPHORAMIDITES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 287 GCC COUNTRIES: RNA PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 288 MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 289 NORTH AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 290 EUROPE: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 291 ASIA PACIFIC: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 292 LATIN AMERICA: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 293 MIDDLE EAST: MODIFIED PHOSPHORAMIDITES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 294 GCC COUNTRIES: MODIFIED PHOSPHORAMIDITES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 295 ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 296 NORTH AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 297 EUROPE: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 298 ASIA PACIFIC: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 299 LATIN AMERICA: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 300 MIDDLE EAST: ACTIVATORS/COUPLING REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 301 GCC COUNTRIES: ACTIVATORS/COUPLING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 302 DEPROTECTION REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 303 NORTH AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 304 EUROPE: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 305 ASIA PACIFIC: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 306 LATIN AMERICA: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 307 MIDDLE EAST: DEPROTECTION REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 308 GCC COUNTRIES: DEPROTECTION REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 309 CAPPING REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 310 NORTH AMERICA: CAPPING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 311 EUROPE: CAPPING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 312 ASIA PACIFIC: CAPPING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 313 LATIN AMERICA: CAPPING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 314 MIDDLE EAST: CAPPING REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 315 GCC COUNTRIES: CAPPING REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 316 OTHER REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 317 NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 318 EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 319 ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 320 LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 321 MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 322 GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 323 SOLID SUPPORTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 324 NORTH AMERICA: SOLID SUPPORTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 325 EUROPE: SOLID SUPPORTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 326 ASIA PACIFIC: SOLID SUPPORTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 327 LATIN AMERICA: SOLID SUPPORTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 328 MIDDLE EAST: SOLID SUPPORTS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 329 GCC COUNTRIES: SOLID SUPPORTS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 330 OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 331 NORTH AMERICA: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 332 EUROPE: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 333 ASIA PACIFIC: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 334 LATIN AMERICA: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 335 MIDDLE EAST: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 336 GCC COUNTRIES: OLIGO-SPECIFIC PURIFICATION & QC CONSUMABLES MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 337 OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 338 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 339 EUROPE: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 340 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 341 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 342 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 343 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 344 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 345 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 346 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 347 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 348 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 349 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 350 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 351 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 352 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
- TABLE 353 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 354 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 355 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 356 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 357 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY REGION, 2024-2031 (USD MILLION)
- TABLE 358 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR THERAPEUTIC DEVELOPMENT, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 359 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 360 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 361 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 362 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 363 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 364 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 365 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 366 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 367 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 368 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 369 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 370 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 371 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 372 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 373 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 374 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 375 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 376 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 377 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 378 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 379 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2024-2031 (USD MILLION)
- TABLE 380 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 381 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 382 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 383 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 384 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 385 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 386 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 387 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR DIAGNOSTIC COMPANIES & CLINICAL LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 388 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 389 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 390 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 391 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 392 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 393 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
- TABLE 394 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 395 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 396 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 397 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 398 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 399 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 400 NORTH AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 401 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 402 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 403 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 404 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 405 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 406 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 407 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 408 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 409 NORTH AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 410 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 411 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 412 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 413 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 414 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 415 US: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 416 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 417 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 418 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 419 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 420 US: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 421 US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 422 US: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 423 US: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 424 US: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 425 US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 426 US: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 427 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 428 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 429 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 430 CANADA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 431 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 432 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 433 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 434 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 435 CANADA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 436 CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 437 CANADA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 438 CANADA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 439 CANADA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 440 CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 441 CANADA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 442 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 443 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 444 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 445 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 446 EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 447 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 448 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 449 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 450 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 451 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 452 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 453 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 454 EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 455 EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 456 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 457 EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 458 GERMANY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 459 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 460 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 461 GERMANY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 462 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 463 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 464 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 465 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 466 GERMANY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 467 GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 468 GERMANY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 469 GERMANY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 470 GERMANY: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 471 GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 472 GERMANY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 473 UK: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 474 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 475 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 476 UK: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 477 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 478 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 479 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 480 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 481 UK: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 482 UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 483 UK: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 484 UK: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 485 UK: PHOSPHORAMIDITE BUILDING BLOCKSMARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 486 UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 487 UK: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 488 FRANCE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 489 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 490 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 491 FRANCE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 492 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 493 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 494 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 495 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 496 FRANCE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 497 FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 498 FRANCE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 499 FRANCE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 500 FRANCE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 501 FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 502 FRANCE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 503 ITALY: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 504 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 505 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 506 ITALY: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 507 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 508 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 509 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 510 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 511 ITALY: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 512 ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 513 ITALY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 514 ITALY: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 515 ITALY: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY PHTYPE, 2024-2031 (USD MILLION)
- TABLE 516 ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 517 ITALY: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 518 SPAIN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 519 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 520 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 521 SPAIN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 522 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 523 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 524 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 525 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 526 SPAIN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 527 SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 528 SPAIN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 529 SPAIN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 530 SPAIN: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 531 SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 532 SPAIN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 533 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 534 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 535 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 536 REST OF EUROPE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 537 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 538 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 539 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 540 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 541 REST OF EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 542 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 543 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 544 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 545 REST OF EUROPE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 546 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 547 REST OF EUROPE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 548 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 549 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 550 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 551 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 552 ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 553 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 554 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 555 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 556 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 557 ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 558 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 559 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 560 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 561 ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 562 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 563 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 564 JAPAN: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 565 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 566 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 567 JAPAN: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 568 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 569 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 570 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 571 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 572 JAPAN: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 573 JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 574 JAPAN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 575 JAPAN: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 576 JAPAN: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 577 JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 578 JAPAN: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 579 CHINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 580 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 581 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 582 CHINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 583 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 584 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 585 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 586 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 587 CHINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 588 CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 589 CHINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 590 CHINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 591 CHINA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY PHOTYPE, 2024-2031 (USD MILLION)
- TABLE 592 CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 593 CHINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 594 INDIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 595 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 596 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 597 INDIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 598 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 599 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 600 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 601 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 602 INDIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 603 INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 604 INDIA: OLIGONUCLEOTIDE REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 605 INDIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 606 INDIA: PHOSPHORAMIDITE BUILDING BLOCKSMARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 607 INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 608 INDIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 609 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 610 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 611 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 612 SOUTH KOREA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 613 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 614 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 615 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 616 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
List of Figures
- TABLE 617 SOUTH KOREA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 618 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 619 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 620 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 621 SOUTH KOREA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 622 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 623 SOUTH KOREA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 624 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 625 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 626 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 627 AUSTRALIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 628 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 629 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 630 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 631 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 632 AUSTRALIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 633 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 634 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 635 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 636 AUSTRALIA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 637 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 638 AUSTRALIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 639 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 640 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 641 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 642 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 643 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 644 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 645 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 646 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 647 REST OF ASIA PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 648 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 649 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 650 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 651 REST OF ASIA PACIFIC: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 652 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 653 REST OF ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 654 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 655 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 656 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 657 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 658 LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 659 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 660 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 661 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 662 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 663 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 664 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 665 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 666 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 667 LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 668 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 669 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 670 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 671 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 672 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 673 BRAZIL: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 674 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 675 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 676 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 677 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 678 BRAZIL: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 679 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 680 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 681 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 682 BRAZIL: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 683 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 684 BRAZIL: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 685 MEXICO: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 686 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 687 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 688 MEXICO: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 689 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 690 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 691 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 692 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 693 MEXICO: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 694 MEXICO: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 695 MEXICO: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 696 MEXICO: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 697 MEXICO: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 698 MEXICO: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 699 MEXICO: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 700 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 701 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 702 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 703 ARGENTINA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 704 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 705 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 706 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 707 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 708 ARGENTINA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 709 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 710 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 711 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 712 ARGENTINA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 713 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 714 ARGENTINA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 715 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 716 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 717 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 718 REST OF LATIN AMERICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 719 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 720 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 721 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 722 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 723 REST OF LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 724 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 725 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 726 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 727 REST OF LATIN AMERICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 728 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 729 REST OF LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 730 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2024-2031 (USD MILLION)
- TABLE 731 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 732 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 733 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 734 MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 735 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 736 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 737 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 738 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 739 MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 740 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 741 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 742 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 743 MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 744 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 745 MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 746 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
- TABLE 747 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 748 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 749 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 750 GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 751 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 752 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 753 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 754 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 755 GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 756 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 757 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 758 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 759 GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 760 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 761 GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 762 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 763 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 764 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 765 SAUDI ARABIA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 766 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 767 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 768 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 769 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 770 SAUDI ARABIA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 771 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 772 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 773 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 774 SAUDI ARABIA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 775 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 776 SAUDI ARABIA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 777 UAE: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 778 UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 779 UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 780 UAE: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 781 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 782 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 783 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 784 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 785 UAE: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 786 UAE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 787 UAE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 788 UAE: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 789 UAE: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 790 UAE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 791 UAE: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 792 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 793 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 794 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 795 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 796 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 797 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 798 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 799 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 800 REST OF GCC COUNTRIES: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 801 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 802 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 803 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 804 REST OF GCC COUNTRIES: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 805 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 806 REST OF GCC COUNTRIES: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 807 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 808 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 809 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 810 REST OF MIDDLE EAST: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 811 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 812 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 813 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 814 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 815 REST OF MIDDLE EAST: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 816 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 817 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 818 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 819 REST OF MIDDLE EAST: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 820 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 821 REST OF MIDDLE EAST: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 822 AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY OFFERING, 2024-2031 (USD MILLION)
- TABLE 823 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 824 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY THERAPEUTIC AREA, 2024-2031 (USD MILLION)
- TABLE 825 AFRICA: OLIGONUCLEOTIDE-BASED DRUGS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 826 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 827 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY OLIGO TYPE, 2024-2031 (USD MILLION)
- TABLE 828 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 829 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 830 AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 831 AFRICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 832 AFRICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS & CONSUMABLES MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 833 AFRICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 834 AFRICA: PHOSPHORAMIDITE BUILDING BLOCKS MARKET, BY TYPE, 2024-2031 (USD MILLION)
- TABLE 835 AFRICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
- TABLE 836 AFRICA: OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET, BY END USER, 2024-2031 (USD MILLION)
- TABLE 837 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023-2026
- TABLE 838 KEY PLAYER STRATEGIES IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023-2026
- TABLE 839 OLIGONUCLEOTIDE-BASED DRUGS MARKET: DEGREE OF COMPETITION
- TABLE 840 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: DEGREE OF COMPETITION
- TABLE 841 OLIGONUCLEOTIDE-BASED DRUGS MARKET: REGION FOOTPRINT
- TABLE 842 OLIGONUCLEOTIDE-BASED DRUGS MARKET: DRUG TYPE FOOTPRINT
- TABLE 843 OLIGONUCLEOTIDE-BASED DRUGS MARKET: THERAPEUTIC AREA FOOTPRINT
- TABLE 844 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: REGION FOOTPRINT
- TABLE 845 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES: BY PRODUCT TYPE FOOTPRINTS
- TABLE 846 DETAILED LIST OF KEY STARTUPS/SMES
- TABLE 847 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
- TABLE 848 OLIGONUCLEOTIDE SYNTHESIS MARKET: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 849 OLIGONUCLEOTIDE SYNTHESIS MARKET: DEALS, JANUARY 2023-JULY 2026
- TABLE 850 OLIGONUCLEOTIDE SYNTHESIS MARKET: EXPANSIONS, JANUARY 2022-MAY 2025
- TABLE 851 ALNYLAM PHARMACEUTICALS, INC.: COMPANY OVERVIEW
- TABLE 852 ALNYLAM PHARMACEUTICALS, INC.: PRODUCTS OFFERED
- TABLE 853 ALNYLAM PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 854 ALNYLAM PHARMACEUTICALS, INC.: DEALS, JANUARY 2023-JULY 2026
- TABLE 855 ALNYLAM PHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 856 BIOGEN INC.: COMPANY OVERVIEW
- TABLE 857 BIOGEN INC.: PRODUCTS OFFERED
- TABLE 858 BIOGEN INC.: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 859 BIOGEN INC.: DEALS, JANUARY 2023-JULY 2026
- TABLE 860 BIOGEN INC.: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 861 NOVARTIS AG: COMPANY OVERVIEW
- TABLE 862 NOVARTIS AG: PRODUCTS OFFERED
- TABLE 863 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 864 NOVARTIS AG: DEALS, JANUARY 2023-JULY 2026
- TABLE 865 SAREPTA THERAPEUTICS, INC.: COMPANY OVERVIEW
- TABLE 866 SAREPTA THERAPEUTICS, INC.: PRODUCTS OFFERED
- TABLE 867 SAREPTA THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 868 SAREPTA THERAPEUTICS, INC.: DEALS, JANUARY 2023-JULY 2026
- TABLE 869 SAREPTA THERAPEUTICS: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 870 ASTELLAS PHARMA INC.: COMPANY OVERVIEW
- TABLE 871 ASTELLAS PHARMA INC.: PRODUCTS OFFERED
- TABLE 872 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 873 ASTELLAS PHARMA INC.: DEALS, JANUARY 2023-JULY 2026
- TABLE 874 ASTRAZENECA: COMPANY OVERVIEW
- TABLE 875 ASTRAZENECA: PRODUCTS OFFERED
- TABLE 876 ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 877 ASTRAZENECA: DEALS, JANUARY 2023-JULY 2026
- TABLE 878 JAZZ PHARMACEUTICALS PLC: COMPANY OVERVIEW
- TABLE 879 JAZZ PHARMACEUTICALS PLC: PRODUCTS OFFERED
- TABLE 880 GERON CORPORATION: COMPANY OVERVIEW
- TABLE 881 GERON CORPORATION: PRODUCTS OFFERED
- TABLE 882 GERON CORPORATION: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 883 GERON CORPORATION: DEALS, JANUARY 2023-JULY 2026
- TABLE 884 IONIS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
- TABLE 885 IONIS PHARMACEUTICALS, INC.: PRODUCTS OFFERED
- TABLE 886 IONIS PHARMACEUTICALS, INC.: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 887 IONIS PHARMACEUTICALS, INC.: DEALS, JANUARY 2023-JULY 202
- TABLE 888 IONIS PHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 889 NIPPON SHINYAKU, CO. LTD.: COMPANY OVERVIEW
- TABLE 890 NIPPON SHINYAKU, CO., LTD.: PRODUCTS OFFERED
- TABLE 891 NIPPON SHINYAKU, CO., LTD.: DEALS, JANUARY 2023-JULY 2026
- TABLE 892 NOVO NORDISK A/S: COMPANY OVERVIEW
- TABLE 893 NOVO NORDISK A/S: PRODUCTS OFFERED
- TABLE 894 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 895 ARROWHEAD PHARMACEUTICALS, INC.: COMPANY OVERVIEW
- TABLE 896 ARROWHEAD PHARMACEUTICALS, INC.: PRODUCTS OFFERED
- TABLE 897 ARROWHEAD PHARMACEUTICALS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-JULY 2026
- TABLE 898 ARROWHEAD PHARMACEUTICALS, INC.: DEALS, JANUARY 2023-JULY 2026
- TABLE 899 SANOFI: COMPANY OVERVIEW
- TABLE 900 SANOFI: PRODUCTS OFFERED
- TABLE 901 SANOFI: PRODUCT APPROVALS, JANUARY 2023-JULY 2026
- TABLE 902 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
- TABLE 903 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
- TABLE 904 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 905 MERCK KGAA: COMPANY OVERVIEW
- TABLE 906 MERCK KGAA: PRODUCTS OFFERED
- TABLE 907 MERCK KGAA: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 908 DANAHER CORPORATION: COMPANY OVERVIEW
- TABLE 909 DANAHER CORPORATION: PRODUCTS OFFERED
- TABLE 910 DANAHER CORPORATION: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
- TABLE 911 DANAHER CORPORATION: DEALS, JANUARY 2023-JULY 2026
- TABLE 912 DANAHER CORPORATION: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 913 EUROFINS SCIENTIFIC: COMPANY OVERVIEW
- TABLE 914 EUROFINS SCIENTIFIC: PRODUCTS OFFERED
- TABLE 915 EUROFINS SCIENTIFIC: DEALS, JANUARY 2023-JULY 2026
- TABLE 916 EUROFINS SCIENTIFIC: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 917 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
- TABLE 918 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
- TABLE 919 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023-JULY 2026
- TABLE 920 AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 921 LGC LIMITED: COMPANY OVERVIEW
- TABLE 922 LGC LIMITED: PRODUCTS OFFERED
- TABLE 923 LGC LIMITED: DEALS, JANUARY 2023-JULY 2026
- TABLE 924 TWIST BIOSCIENCE: COMPANY OVERVIEW
- TABLE 925 TWIST BIOSCIENCE: PRODUCTS OFFERED
- TABLE 926 TWIST BIOSCIENCE: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
- TABLE 927 TWIST BIOSCIENCE: DEALS, JANUARY 2023-JULY 2026
- TABLE 928 GENSCRIPT: COMPANY OVERVIEW
- TABLE 929 GENSCRIPT: PRODUCTS OFFERED
- TABLE 930 GENSCRIPT: PRODUCT/SERVICE LAUNCHES, JANUARY 2023-JULY 2026
- TABLE 931 GENSCRIPT: DEALS, JANUARY 2023-JULY 2026
- TABLE 932 GENSCRIPT: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 933 MARAVAI LIFESCIENCES: COMPANY OVERVIEW
- TABLE 934 MARAVAI LIFESCIENCES: PRODUCTS OFFERED
- TABLE 935 MARAVAI LIFESCIENCES: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
- TABLE 936 MARAVAI LIFESCIENCES: DEALS, JANUARY 2023-JULY 2026
- TABLE 937 MARAVAI LIFESCIENCES: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 938 KANEKA CORPORATION: COMPANY OVERVIEW
- TABLE 939 KANEKA CORPORATION: PRODUCTS OFFERED
- TABLE 940 KANEKA CORPORATION: EXPANSIONS, JANUARY 2023-JULY 2026
- TABLE 941 AZENTA US INC.: COMPANY OVERVIEW
- TABLE 942 AZENTA US INC.: PRODUCTS OFFERED
- TABLE 943 AZENTA US INC.: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
- TABLE 944 AZENTA US INC.: DEALS, JANUARY 2023-JULY 2026
- TABLE 945 OLIGOMAKER APS: COMPANY OVERVIEW
- TABLE 946 OLIGOMAKER APS: PRODUCTS OFFERED
- TABLE 947 BIOLEGIO B.V.: COMPANY OVERVIEW
- TABLE 948 BIOLEGIO B.V.: PRODUCTS OFFERED
- TABLE 949 BIOLYTIC LAB PERFORMANCE, INC.: COMPANY OVERVIEW
- TABLE 950 BIOLYTIC LAB PERFORMANCE, INC.: PRODUCTS OFFERED
- TABLE 951 BIOLYTIC LAB PERFORMANCE, INC.: SERVICE LAUNCHES, JANUARY 2023-JULY 2026
- TABLE 952 REVVITY: COMPANY OVERVIEW
- TABLE 953 REVVITY: PRODUCTS OFFERED
- TABLE 954 REVVITY: PRODUCT LAUNCHES, JANUARY 2023-JULY 2026
- TABLE 955 BIO-SYNTHESIS, INC.: COMPANY OVERVIEW
- TABLE 956 BIO-SYNTHESIS, INC.: PRODUCTS OFFERED
- TABLE 957 CREATIVE BIOGENE: COMPANY OVERVIEW
- TABLE 958 CREATIVE BIOGENE: PRODUCTS OFFERED
- TABLE 959 REPROCELL INC.: COMPANY OVERVIEW
- TABLE 960 REPROCELL INC.: PRODUCTS OFFERED
- TABLE 961 BIOCOMMA LIMITED: COMPANY OVERVIEW
- TABLE 962 BIOCOMMA LIMITED: PRODUCTS OFFERED
- TABLE 963 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
- TABLE 964 RISK ASSESSMENT
List of Figures
- FIGURE 1 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION & REGIONS CONSIDERED
- FIGURE 2 REGIONS CONSIDERED
- FIGURE 3 OLIGONUCLEOTIDE SYNTHESIS MARKET: YEARS CONSIDERED
- FIGURE 4 MARKET SCENARIO
- FIGURE 5 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, 2024-2031
- FIGURE 6 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2023-2026
- FIGURE 7 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2023-2026
- FIGURE 8 DISRUPTIONS INFLUENCING GROWTH OF OLIGONUCLEOTIDE SYNTHESIS MARKET
- FIGURE 9 HIGH-GROWTH SEGMENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET, 2026-2031
- FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN OLIGONUCLEOTIDE SYNTHESIS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
- FIGURE 11 RISING COMMERCIALIZATION AND REGULATORY APPROVALS OF OLIGONUCLEOTIDE THERAPEUTICS TO PROPEL MARKET GROWTH
- FIGURE 12 US AND OLIGONUCLEOTIDE-BASED DRUGS SEGMENT COMMANDED LARGEST MARKET SHARES IN 2025
- FIGURE 13 MEXICO TO REGISTER HIGHER CAGR DURING FORECAST PERIOD
- FIGURE 14 OLIGONUCLEOTIDE-BASED DRUGS TO DOMINATE MARKET DURING FORECAST PERIOD
- FIGURE 15 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
- FIGURE 16 OLIGONUCLEOTIDE-BASED DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 17 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: PORTER'S FIVE FORCES ANALYSIS
- FIGURE 18 OLIGONUCLEOTIDE SYNTHESIS MARKET: VALUE CHAIN ANALYSIS
- FIGURE 19 OLIGONUCLEOTIDE SYNTHESIS MARKET: ECOSYSTEM ANALYSIS
- FIGURE 20 OLIGONUCLEOTIDE-BASED DRUGS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- FIGURE 21 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- FIGURE 22 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE
- FIGURE 23 IMPACT OF AI/GEN AI ON OLIGONUCLEOTIDE SYNTHESIS MARKET
- FIGURE 24 TOP APPLICANTS/OWNER (COMPANIES) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS, 2015-2025
- FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
- FIGURE 26 KEY BUYING CRITERIA, BY END USER
- FIGURE 27 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
- FIGURE 28 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SNAPSHOT
- FIGURE 29 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE-BASED DRUGS MARKET, 2021-2025
- FIGURE 30 REVENUE ANALYSIS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET, 2021-2025
- FIGURE 31 OLIGONUCLEOTIDE-BASED DRUGS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025
- FIGURE 32 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2025
- FIGURE 33 OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
- FIGURE 34 OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY FOOTPRINT
- FIGURE 35 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
- FIGURE 36 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: COMPANY FOOTPRINT
- FIGURE 37 OLIGONUCLEOTIDE SYNTHESIS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
- FIGURE 38 OLIGONUCLEOTIDE-BASED DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
- FIGURE 39 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
- FIGURE 40 EV/EBITDA OF KEY VENDORS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET
- FIGURE 41 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGONUCLEOTIDES MARKET
- FIGURE 42 EV/EBITDA OF KEY VENDORS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET
- FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS IN OLIGONUCLEOTIDE-BASED DRUGS MARKET
- FIGURE 44 ALNYLAM PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 45 BIOGEN INC.: COMPANY SNAPSHOT (2025)
- FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2025)
- FIGURE 47 SAREPTA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 48 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2025)
- FIGURE 49 ASTRAZENECA: COMPANY SNAPSHOT (2025)
- FIGURE 50 JAZZ PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2025)
- FIGURE 51 GERON CORPORATION: COMPANY SNAPSHOT (2025)
- FIGURE 52 IONIS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 53 NIPPON SHINYAKU, CO. LTD.: COMPANY SNAPSHOT (2025)
- FIGURE 54 NOVO NORDISK A/S: COMPANY SNAPSHOT (2025)
- FIGURE 55 ARROWHEAD PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 56 SANOFI: COMPANY SNAPSHOT (2025)
- FIGURE 57 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
- FIGURE 58 MERCK KGAA: COMPANY SNAPSHOT (2025)
- FIGURE 59 DANAHER CORPORATION: COMPANY SNAPSHOT (2025)
- FIGURE 60 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2025)
- FIGURE 61 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025)
- FIGURE 62 LGC LIMITED: COMPANY SNAPSHOT (2025)
- FIGURE 63 TWIST BIOSCIENCE: COMPANY SNAPSHOT (2025)
- FIGURE 64 GENSCRIPT: COMPANY SNAPSHOT (2025)
- FIGURE 65 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT (2025)
- FIGURE 66 KANEKA CORPORATION: COMPANY SNAPSHOT (2025)
- FIGURE 67 AZENTA US INC.: COMPANY SNAPSHOT (2025)
- FIGURE 68 REVVITY: COMPANY SNAPSHOT (2025)
- FIGURE 69 REPROCELL INC.: COMPANY SNAPSHOT (2025)
- FIGURE 70 OLIGONUCLEOTIDE SYNTHESIS MARKET: RESEARCH DESIGN
- FIGURE 71 OLIGONUCLEOTIDE SYNTHESIS MARKET: BREAKDOWN OF PRIMARIES
- FIGURE 72 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET ESTIMATION, 2025
- FIGURE 73 OLIGONUCLEOTIDE-BASED DRUGS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
- FIGURE 74 SYNTHESIZED OLIGONUCLEOTIDES & OLIGONUCLEOTIDE SYNTHESIS PRODUCTS MARKET: COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH) (2025)
- FIGURE 75 OLIGONUCLEOTIDE SYNTHESIS MARKET: INSIGHTS FROM PRIMARIES
- FIGURE 76 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH
- FIGURE 77 OLIGONUCLEOTIDE-BASED DRUGS MARKET: CAGR PROJECTIONS
- FIGURE 78 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SYNTHESIZED OLIGOS MARKET: CAGR PROJECTIONS
- FIGURE 79 OLIGONUCLEOTIDE SYNTHESIS MARKET: DATA TRIANGULATION
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.